SkyePharma reduces losses and posts increased revenue
This article was originally published in Scrip
Executive Summary
SkyePharma's revenues for the first half grew by 44% to £28.4 million despite generic competition to its antidepressant Paxil CR (paroxetine), which is marketed byGlaxoSmithKline, being introduced in the US by Mylan Pharmaceuticalsin May.